PBE News and Press, Invesco Dynamic Biotech & Genome From 03/20/23

2023-03-20 16:17:23 ET Invesco Dynamic Biotechnology & Genome ETF ( NYSEARCA: PBE ) - $0.0289 . 30-Day SEC Yield of -0.25% as of Mar 17. Payable Mar 24; for shareholders of record Mar 21; ex-div Mar 20. For further details see: Invesco Dynamic Biotechnolo...

2023-03-20 06:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-03-16 15:51:00 ET Summary How SVB's collapse is impacting healthcare startups. Pfizer to buy Seagen for $43B. What it means for the sector. Why healthcare startups could face funding challenges. The collapse of Silicon Valley Bank is raising concerns about fun...

2023-03-16 06:31:14 ET Summary The pharma/biotech subsector is undervalued by 16% relative to 11-year averages. Healthcare equipment is the less attractive subsector regarding both valuation and quality. Fast facts on PBE, a biotechnology and genomics ETF. 10 stocks cheape...

2023-03-11 04:42:25 ET Summary Fed's aggressive rate hikes, plus SVB crisis, are a big worry right now. Behind the scenes, a (related) biotech stock crisis is also brewing. Market internals remain weak and demand caution going forward. What do a major U.S. commercial...

2023-03-10 14:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-03-09 02:50:00 ET Summary Rates of change matter, especially for tech companies, and we would expect investors to react favorably to accelerating growth. In healthcare, we continue to find investment opportunities in a difficult macro environment. If the U.S. enters a tra...

2023-03-09 02:20:00 ET Summary Increasing selling pressure among biotech stocks is a major concern. While the market's intermediate-term path is still up, the short-term outlook is weakening. Beware higher volatility in March as healthcare sector selling pressure persists. ...

Summary We think healthcare companies are quite resilient during periods of inflation because their products are not substitutable and they deliver innovation. Healthcare has lagged behind many other areas in terms of its adoption of technology. We think, regardless of the market en...

Summary We think value stocks can outperform as interest rates head higher. Regions and sectors help us find quality within value and growth at a reasonable price. Stocks slid after the Federal Reserve’s preferred inflation gauge showed persistently high inflation, reinforcing wh...